The short answer
Potassium monitoring and correction of low levels may be needed during adagrasib treatment. Your oncology team should decide whether supplementation is necessary from your results and risk factors.
What this answer covers
Adequate potassium intake and clinician-directed replacement during oral adagrasib therapy. Dietary intake, oral supplements and treatment of clinically significant electrolyte abnormalities are distinct decisions.
- Supplement or preparation
- Potassium
- Medication ingredient
- adagrasib
Why this electrolyte matters
Krazati can prolong the QT interval, an electrical measurement of the heartbeat. Its label specifically identifies potassium and magnesium as electrolytes to assess and correct when abnormal. This is a reason to follow the care team’s blood-test and ECG plan, especially with other heart-rhythm risks.
Low levels can occur during treatment
The label’s study results include decreases in potassium. Krazati also commonly causes nausea, vomiting or diarrhea, so persistent digestive symptoms should be reported. A low laboratory result needs clinical interpretation; it does not mean every person taking the medicine has the same problem.
A supplement is an individual decision
Ask your oncology team whether your results call for dietary advice, a prescribed replacement product or another intervention. The label does not give everyone a routine potassium supplement or a single preventive dose. Bring all mineral products and other medicines to the review so the plan reflects your full treatment.
Do not manage heart symptoms with supplements
A racing or irregular heartbeat, fainting or sudden marked dizziness warrants prompt medical assessment. Taking extra potassium or spacing it from adagrasib is not a substitute for checking the cause. Keep the agreed monitoring appointments and let the cancer team decide whether treatment needs to change.
Evidence and practical considerations
Timing & monitoring
Adagrasib treatment may require potassium monitoring and correction of low levels, especially when heart-rhythm or GI risk factors are present.
- Exact scope
- Adequate potassium intake and clinician-directed replacement during oral adagrasib therapy. Dietary intake, oral supplements and treatment of clinically significant electrolyte abnormalities are distinct decisions. with Exact adagrasib RxCUI 2625882 IN, confirmed by current RxNorm properties. Oral Krazati tablets; the August 2026 U.S. label covers single-agent treatment of specified previously treated KRAS G12C-mutated NSCLC. Older cetuximab combination cohorts and regional label instructions are not interchangeable.
- Medication form and route
- Oral
What remains uncertain
- Current label supports testing and correcting abnormalities, not routine supplements for every user, a universal dose or proof that dietary intake alone prevents QT prolongation.
Factors that may matter: Exact preparation and dose; Treatment phase and duration; Liver function; Electrolyte results and GI symptoms; Other medicines.
Read the supporting source summaries
Source 1: Current U.S. prescribing information
bms.com · Source check Sep 10, 2026
Population: Adults with specified previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Warns about GI toxicity, QT prolongation and hepatotoxicity. Monitor/correct electrolytes, particularly potassium and magnesium, and monitor liver tests. Strong CYP3A inducers lower exposure. Avoid strong CYP3A inhibitors until steady state, approximately eight days. High-fat meal did not meaningfully change exposure; tablets may be taken with or without food.
How this applies: Exact current U.S. guidance; newer than the retained March 2026 DailyMed version. Exact adagrasib RxCUI 2625882 IN, confirmed by current RxNorm properties. Oral Krazati tablets; the August 2026 U.S. label covers single-agent treatment of specified previously treated KRAS G12C-mutated NSCLC. Older cetuximab combination cohorts and regional label instructions are not interchangeable.
Not direct evidence of each botanical combination. Strong-inhibitor effects after a single dose differ from steady-state model predictions. Effects of adagrasib on other CYP substrates are a separate direction. No universal supplement prescription.
Source 2: Authoritative medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Medication terminology.
Identifies adagrasib as IN.
How this applies: Exact identity confirmation.
Not clinical interaction evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: d5ab3c048d3e5aad
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.